Sodium-Glucose Cotransporter-2 Inhibitors and the Risk of Abnormal Serum Potassium Level.

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) impede glucose reabsorption in kidney proximal tubules, which in turn can stimulate osmotic diuresis, natriuresis, and the renin-angiotensin system. This mechanism may enhance potassium secretion via increased distal sodium and water delivery and